Karin Rosén

5.8k total citations · 5 hit papers
40 papers, 3.7k citations indexed

About

Karin Rosén is a scholar working on Physiology, Rheumatology and Immunology and Allergy. According to data from OpenAlex, Karin Rosén has authored 40 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 19 papers in Rheumatology and 15 papers in Immunology and Allergy. Recurrent topics in Karin Rosén's work include Urticaria and Related Conditions (19 papers), Asthma and respiratory diseases (19 papers) and Allergic Rhinitis and Sensitization (12 papers). Karin Rosén is often cited by papers focused on Urticaria and Related Conditions (19 papers), Asthma and respiratory diseases (19 papers) and Allergic Rhinitis and Sensitization (12 papers). Karin Rosén collaborates with scholars based in United States, Germany and United Kingdom. Karin Rosén's co-authors include Marcus Maurer, Allen P. Kaplan, Sarbjit S. Saini, William W. Busse, Hsin-Ju Hsieh, Nicola A. Hanania, Janice Canvin, Thomas B. Casale, Benjamin Trzaskoma and Dennis A. Wong and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Karin Rosén

40 papers receiving 3.7k citations

Hit Papers

Omalizumab for the Treatm... 2011 2026 2016 2021 2013 2013 2011 2013 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
    2013 714 citations Marcus Maurer, Karin Rosén et al. New England Journal of Medicine profile →
  2. Exploring the Effects of Omalizumab in Allergic Asthma
    2013 669 citations Nicola A. Hanania, Sally E. Wenzel et al. American Journal of Respiratory and Critical Care Medicine profile →
  3. Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
    2011 429 citations Nicola A. Hanania, Oral Alpan et al. profile →
  4. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
    2013 392 citations Allen P. Kaplan, Dennis K. Ledford et al. Journal of Allergy and Clinical Immunology profile →
  5. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study
    2014 307 citations Sarbjit S. Saini, Carsten Bindslev‐Jensen et al. Journal of Investigative Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Karin Rosén 2.0k 1.9k 1.3k 1.1k 1.1k 40 3.7k
Yohei Seto 232 0.1× 784 0.4× 90 0.1× 181 0.2× 180 0.2× 68 1.4k
Karina Raimundo 409 0.2× 344 0.2× 718 0.6× 279 0.3× 153 0.1× 59 1.2k
Patricia Rohane 436 0.2× 221 0.1× 266 0.2× 25 0.0× 55 0.1× 10 981
Jonathan Steinfeld 545 0.3× 757 0.4× 809 0.6× 20 0.0× 70 0.1× 36 1.3k
JingYuan Feng 603 0.3× 161 0.1× 327 0.3× 22 0.0× 39 0.0× 11 865
Mathieu Gerfaud‐Valentin 393 0.2× 386 0.2× 368 0.3× 94 0.1× 84 0.1× 74 1.8k
Minako Tomiita 202 0.1× 224 0.1× 124 0.1× 89 0.1× 21 0.0× 53 1.2k
Curry L. Koening 237 0.1× 544 0.3× 889 0.7× 37 0.0× 289 0.3× 43 1.4k
Tuyet‐Hang Pham 478 0.2× 151 0.1× 328 0.3× 20 0.0× 11 0.0× 25 1.1k
Ruchika Goel 89 0.0× 345 0.2× 649 0.5× 58 0.1× 82 0.1× 63 1.1k

Countries citing papers authored by Karin Rosén

Since Specialization
Citations

This map shows the geographic impact of Karin Rosén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Rosén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Rosén more than expected).

Fields of papers citing papers by Karin Rosén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Rosén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Rosén. The network helps show where Karin Rosén may publish in the future.

Co-authorship network of co-authors of Karin Rosén

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Rosén. A scholar is included among the top collaborators of Karin Rosén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Rosén. Karin Rosén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lieberman, Phil, J. Wesley Sublett, Yaser Ali, et al.. (2018). INCREASED INCIDENCE AND PREVALENCE OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS IN THE UNITED STATES. Annals of Allergy Asthma & Immunology. 121(5). S13–S13. 15 indexed citations
2.
Hanania, Nicola A., Karin Rosén, Noelle M. Griffin, et al.. (2018). Response to Omalizumab Observed Over Wide Range of Blood Eosinophil Levels. Journal of Allergy and Clinical Immunology. 141(2). AB15–AB15. 1 indexed citations
3.
Chipps, Bradley E., Tmirah Haselkorn, Karin Rosén, et al.. (2017). Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life. The Journal of Allergy and Clinical Immunology In Practice. 6(1). 169–176.e2. 25 indexed citations
4.
Chipps, Bradley E., Bob Lanier, Henry Milgrom, et al.. (2017). Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. Journal of Allergy and Clinical Immunology. 139(5). 1431–1444. 115 indexed citations
5.
Ledford, Dennis K., William W. Busse, Benjamin Trzaskoma, et al.. (2016). A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. Journal of Allergy and Clinical Immunology. 140(1). 162–169.e2. 146 indexed citations
6.
Giménez‐Arnau, Ana M., Sheldon L. Spector, Evgeniya Antonova, et al.. (2016). Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clinical and Translational Allergy. 6(1). 32–32. 25 indexed citations
7.
Zazzali, James L., Allen P. Kaplan, Marcus Maurer, et al.. (2016). Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Annals of Allergy Asthma & Immunology. 117(4). 370–377.e1. 20 indexed citations
8.
Kaplan, Allen P., Marta Ferrer, Jonathan A. Bernstein, et al.. (2015). Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. Journal of Allergy and Clinical Immunology. 137(2). 474–481. 132 indexed citations
9.
Casale, Thomas B., Jonathan A. Bernstein, Marcus Maurer, et al.. (2015). Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. The Journal of Allergy and Clinical Immunology In Practice. 3(5). 743–750.e1. 64 indexed citations
10.
Mathias, Susan D., Ross D. Crosby, Karin Rosén, & James L. Zazzali. (2015). The minimal important difference for measures of urticaria disease activity: Updated findings. Allergy and Asthma Proceedings. 36(5). 394–398. 19 indexed citations
11.
Busse, William W., Theodore A. Omachi, Janice Canvin, et al.. (2014). Evaluating omalizumab persistency of response after long-term therapy (XPORT). European Respiratory Journal. 44(Suppl 58). P3485–P3485. 9 indexed citations
12.
Saini, Sarbjit S., Carsten Bindslev‐Jensen, Marcus Maurer, et al.. (2014). Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. Journal of Investigative Dermatology. 135(1). 67–75. 307 indexed citations breakdown →
13.
Long, Aidan A., Abdelkader Rahmaoui, Kenneth J. Rothman, et al.. (2014). Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. Journal of Allergy and Clinical Immunology. 134(3). 560–567.e4. 150 indexed citations
14.
Hanania, Nicola A., Sally E. Wenzel, Karin Rosén, et al.. (2013). Exploring the Effects of Omalizumab in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine. 187(8). 804–811. 669 indexed citations breakdown →
15.
Kaplan, Allen P., Dennis K. Ledford, Mark Ashby, et al.. (2013). Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy and Clinical Immunology. 132(1). 101–109. 392 indexed citations breakdown →
16.
Maurer, Marcus, Karin Rosén, Hsin-Ju Hsieh, et al.. (2013). Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine. 368(10). 924–935. 714 indexed citations breakdown →
17.
Zhu, Rui, Yanan Zheng, Wendy S. Putnam, et al.. (2013). Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy. The AAPS Journal. 15(2). 559–570. 9 indexed citations
18.
Rosén, Karin, Hsin-Ju Hsieh, Panayiotis Georgiou, Thomas B. Casale, & Marcus Maurer. (2013). Baseline Characteristics of Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Enrolled in a Phase III, Randomized, Placebo-Controlled Trial of Omalizumab. Journal of Allergy and Clinical Immunology. 131(2). AB29–AB29. 1 indexed citations
19.
Saini, Sarbjit S., Karin Rosén, Dennis A. Wong, et al.. (2011). A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology. 128(3). 567–573.e1. 268 indexed citations
20.
Mathias, Susan D., Stephen C. Dreskin, Allen P. Kaplan, et al.. (2010). Development of a daily diary for patients with chronic idiopathic urticaria. Annals of Allergy Asthma & Immunology. 105(2). 142–148. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yohei Seto Breakdown of academic impact, for papers by Karina Raimundo Breakdown of academic impact, for papers by Patricia Rohane Breakdown of academic impact, for papers by Jonathan Steinfeld Breakdown of academic impact, for papers by JingYuan Feng Breakdown of academic impact, for papers by Mathieu Gerfaud‐Valentin Breakdown of academic impact, for papers by Minako Tomiita Breakdown of academic impact, for papers by Curry L. Koening Breakdown of academic impact, for papers by Tuyet‐Hang Pham Breakdown of academic impact, for papers by Ruchika Goel
Rankless by CCL
2026